Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Virax Biolabs Group's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 16.59.
Virax Biolabs Group's Days Inventory for the
six
months ended in Mar. 2026 was 1971.
Virax Biolabs Group's Days Payable for the
six
months ended in Mar. 2026 was 1715.5.
Therefore, Virax Biolabs Group's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 272.09.
Virax Biolabs Group (NAS:VRAX) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Virax Biolabs Group Cash Conversion Cycle Related Terms
Virax Biolabs Group Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRAX vs ISCO, PKTX, GRI: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Virax Biolabs Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's Cash Conversion Cycle falls into.
Virax Biolabs Group Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Virax Biolabs Group's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virax Biolabs Group (VRAX) has a Cash Conversion Cycle of 272.09 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Cash Conversion Cycle too high?
Virax Biolabs Group's current Cash Conversion Cycle is 272.09. The Biotechnology industry median Cash Conversion Cycle is 105.01. Virax Biolabs Group's value of 272.09 is 159.1% above this industry median. Overall, Virax Biolabs Group has a GF Score™ of 45/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Cash Conversion Cycle compare to ISCO and PKTX?
Virax Biolabs Group's Cash Conversion Cycle of 272.09 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 105.01. Virax Biolabs Group's value of 272.09 is 159.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 105.01, based on 871 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current Cash Conversion Cycle of 272.09 is 159.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 105.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current Cash Conversion Cycle is 272.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.57, compared to a current price of $3.37 — trading 5.6% below its estimated fair value. The current Cash Conversion Cycle is 272.09 and 159.1% above the Biotechnology industry median of 105.01. Virax Biolabs Group's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Cash Conversion Cycle is 272.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued.
The current stock price of $3.37 is trading 5.6% below its estimated GF Value™ of $3.57.
GuruFocus considers Virax Biolabs Group to be Fairly Valued.
Key valuation signals for VRAX:
Cash Conversion Cycle: 272.09
GF Value™: $3.57 vs. price of $3.37 (5.6% below fair value)
Industry Position: 159.1% above the Biotechnology median
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score
Get the complete analysis for VRAX
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
